Also known as Byetta
Exenatide (INN, marketed as Byetta, Bydureon) is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication approved in April 2005 for the treatment of diabetes mellitus type 2. It belongs to the group of incretin mimetics and is manufactured by Amylin Pharmaceuticals. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day. A once-weekly injection has been approved as of January 27, 2012 under the trademark Bydureon.Source: Wikipedia
Estimated Total Cost: $239.73 for an average of 28 days supply
Patients are most commonly prescribed exenatide to treat diabetes, hyperlipidemia, diabetic peripheral neuropathy, and metabolic disorder.